Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@SouthernValue95

SouthernValue on X

$SKYD should probably be a ~$4 stock. Unlike $PARA and $WBD it cannot breakup/sell - the only way out is through. Thats no easy road: starting almost 7x levered and needs to achieve MSD growth and to find $6B synergies from two companies that have already been thoroughly gutted to hit their deleveraging plan. Interest expense 150% of FCF. Rates exploding higher so they better hope they can de-lever. Potential seismic changes to entertainment in next 3-5yrs from generative content and short-form competition are existential threats. With any decline in revenue $SKYD will not be able to afford its sports rights renewals and the entire legacy business falls apart from there. Putting ~30% odds $NFLX gets another shot at WB studio in eventual bankruptcy. If you disagree and you are optimistic, please share why? I'm openminded but do not currently see it. Mgmt seems shell-shocked in Faber interview this AM getting a few tough questions. https://t.co/RKBucH3xlT
@StableBread

Fajasy on X

I listened to ~17 interviews with Jason Jessup, the CEO of Magna Mining $MGMNF (TSX: $NICU), from October 2025 to September 2026 (for my deep dive). For context, Magna owns McCreedy West, a producing copper mine in Sudbury, Ontario, plus Levack and Crean Hill, two past-producing mines it plans to restart. Here are the most important takeaways I got from those interviews: 1) Levack could be 2-3x McCreedy West: Jessup expects “possibly two to even three times” McCreedy West’s payable metal from Levack (The Resource Update, September 8). 2) R2 isn’t in Levack’s upcoming study: R2, a high-grade zone Magna found at Levack in 2025, could produce “10 to 15% copper equivalent material” even with 1-2 tons of waste mined per ton of vein (KE Report, July 10), 3-4.5x McCreedy West’s grades, and Jessup says the zone carries “no streams or royalties on the precious metals” (KE Report, April 20). 3) No more equity raises, he says: With CAD$140M coming from Alpayana, a private Peruvian mining group, for 19.9% of Magna, Jessup said “we could have five mines in production in 5 years and not have to ever do another financing again” (KE Report, July 10). 4) But three timelines moved back: (1) Levack commercial production went from “a good possibility” by the end of 2027 (KE Report, February 20) to 2028 (KE Report, July 10), (2) Crean Hill grid power from as early as Q1 2026 to Q4, and (3) the R2 resource estimate from the end of 2026 or start of 2027 to “potentially by the end of 2027” (Mining Stock Daily, August 13). 5) Skin in the game: Jessup says he owns ~10.6M shares, has “never sold a share,” and wants “a $5 billion company” by 2030 (Natural Resource Stocks, July 20), 6.5x Magna’s CAD$768M market cap at CAD$2.45/share. Levack’s PEA and Crean Hill’s pre-feasibility study are both due in October, and Jessup expects a formal Levack restart decision “shortly after seeing the PEA come out” (Mining Stock Daily, September 24). --- Link in bio to find the deep dive.

Investor Letters

All letters

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $404M
The Oak Bloke 2 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 4 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 3 clicks
T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

T $144B
Value Investors Club

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 71 of 272

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

281 firms

Sectors

Ordered by how often our editor reaches for them.